Stanley Medical Research Institute, Rockville, Maryland.
Treatment Advocacy Center, Arlington, Virginia.
Prim Care Companion CNS Disord. 2023 Aug 1;25(4):23m03486. doi: 10.4088/PCC.23m03486.
To examine the funding priorities of the National Institute of Mental Health (NIMH) since 2016 to assess whether NIMH was continuing to prioritize basic research at the expense of clinical research. Six psychiatric disorders (schizophrenia, bipolar disorder, depression, anxiety disorders, eating disorders, autism) were assessed using 2 publicly available data sources (ClinicalTrials.gov and the National Institutes of Health Research, Condition, and Disease Categorization [RCDC]) to determine the degree of NIMH support for drug trials and research on these disorders in general since 2016. From 2017 through 2022, ClinicalTrials.gov lists just 1 drug trial each for schizophrenia and bipolar disorder. The RCDC database for 2016 through 2021 shows that NIMH support for research projects on schizophrenia and bipolar disorder decreased by 22% and 20%, respectively. During that time, Congress increased the budget of NIMH by 40%. NIMH has continued to prioritize basic research over clinical trials, resulting in a steep decline in funding for possible treatments for the most serious and costly psychiatric diseases. .
为了研究美国国家心理健康研究所（NIMH）自 2016 年以来的资金重点，以评估 NIMH 是否继续优先考虑基础研究而牺牲临床研究。使用 2 个公开可用的数据源（ClinicalTrials.gov 和美国国立卫生研究院研究、状况和疾病分类[RCDC]）评估了 6 种精神障碍（精神分裂症、双相情感障碍、抑郁症、焦虑症、饮食失调症、自闭症），以确定自 2016 年以来 NIMH 对这些疾病的药物试验和一般研究的支持程度。从 2017 年到 2022 年，ClinicalTrials.gov 仅列出了精神分裂症和双相情感障碍各 1 项药物试验。2016 年至 2021 年的 RCDC 数据库显示，NIMH 对精神分裂症和双相情感障碍研究项目的支持分别减少了 22%和 20%。在此期间，国会将 NIMH 的预算增加了 40%。NIMH 继续优先考虑基础研究而不是临床试验，导致针对最严重和最昂贵的精神疾病的潜在治疗方法的资金大幅减少。
